DSM acquires next-generation eubiotics platform start-up
Retrieved on:
Tuesday, July 27, 2021
DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
Key Points:
- DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
- Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals.
- Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.
- Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group) .